Similarly, a low ESR2 expression level was considered a favorable prognostic factor in PRAD (only male samples) (p-value = 0.024) (Figure S3), while a high ESR2 expression level was significantly correlated with longer DFS in TGCT (p-value = 0.004) (Figure S3) (only male samples). Here, ESR2 is linked to prostate adenocarcinoma.